Abstract
Migraine is a common type of headache and its most severe attacks are usually treated with triptans, the efficacy of which is extremely variable. Several SNPs in genes involved in metabolism and target mechanisms of triptans have been described. To define an association between genetic profile and triptan response, we classified a migrainous population on the basis of triptan response and characterized it for polymorphisms in the genes coding for monoamine oxidase A, G protein β3 and the cytochrome CYP1A2. Analysis of the association between genotypic and allelic frequencies of the analyzed SNPs and the grade of response to triptan administration showed a significant correlation for MAOA uVNTR polymorphism. Further stratification of patients in abuser and non-abuser groups revealed a significant association with triptan overuse and, within the abusers, with drug response to the CYP1A2*1F variant.
Keywords: Chronic migraine, SNPs, Triptan overuse, Triptan efficacy, Polymorphisms
Full Text
The Full Text of this article is available as a PDF (175.6 KB).
Conflict of interest
GG, MB, NL and MS have declared no conflict of interest. SM won an unconditioned 2 years university fellowship funded by Merck Sharp & Dohme. PM has received honoraria for contribution to advisory boards and research projects, and participation in clinical trials from Abbott, Allergan, ACRAF, Guidotti, Lusofarmaco and Merck Sharp & Dohme. PM has also received unconditioned educational funds for young researcher fellowships from the University Department of ACRAF, Allergan, Bayer, Lusofarmaco and Merck Sharp & Dohme.
References
- 1.Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res. 2003;48:1–9. [PubMed] [Google Scholar]
- 2.Schürks M, Kurth T, Stude P, Rimmbach C, Jesus J, Jonjic M, Diener HC, Rosskopf D. G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007;82:396–401. doi: 10.1038/sj.clpt.6100159. [DOI] [PubMed] [Google Scholar]
- 3.Headache Classification Committee. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–746. doi: 10.1111/j.1468-2982.2006.01172.x. [DOI] [PubMed] [Google Scholar]
- 4.Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ, International Headache Society The International Classification of Headache Disorders, 2nd edn (ICHD-II)—revision of criteria 8.2 Medication overuse headache. Cephalalgia. 2005;25:460–465. doi: 10.1111/j.1468-2982.2005.00878.x. [DOI] [PubMed] [Google Scholar]
- 5.Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain. 2010;11:151–156. doi: 10.1007/s10194-010-0202-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rodriguez S, Gaunt TR, Day INM. Hardy–Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009;169:505–514. doi: 10.1093/aje/kwn359. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998;18:45–48. doi: 10.1038/ng0198-45. [DOI] [PubMed] [Google Scholar]
- 8.Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998;103:273–279. doi: 10.1007/s004390050816. [DOI] [PubMed] [Google Scholar]
- 9.Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445–449. doi: 10.1046/j.1365-2125.1999.00898.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Di Lorenzo C, Di Lorenzo G, Sances G, Ghiotto N, Guaschino E, Grieco GS, Santorelli FM, Casali C, Troisi A, Siracusano A, Pierelli F. Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J Headache Pain. 2009;10:349–355. doi: 10.1007/s10194-009-0136-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hagen K, Jensen R, Bøe MG, Stovner LJ (2010) Medication overuse headache: a critical review of end points in recent follow-up studies. J Headache Pain. doi:10.1007/s10194-010-0221-4 [DOI] [PMC free article] [PubMed]
- 12.Antonaci F, Dumitrache C, Cillis I, Allena M. Review of current European treatment guidelines for migraine. J Headache Pain. 2010;11:13–19. doi: 10.1007/s10194-009-0179-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bigal ME, Ho TW. Is there an inherent limit in the migraine acute treatment efficacy? J Headache Pain. 2009;10:393–394. doi: 10.1007/s10194-009-0162-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Stovner LJ, Tronvik E, Hagen H. New drugs for migraine. J Headache Pain. 2009;10:395–406. doi: 10.1007/s10194-009-0156-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Tfelt-Hansen P. What can be learned from the history of recurrence of migraine? A comment. J Headache Pain. 2009;10:311–315. doi: 10.1007/s10194-009-0144-0. [DOI] [PMC free article] [PubMed] [Google Scholar]